Global Erythropoietin (EPO) Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2026

MarketResearch.biz delivers in-depth insights on the global erythropoietin (EPO) drugs market in its upcoming report titled, “Global Erythropoietin (EPO) Drugs Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, and Growth Forecast to 2027”. The global erythropoietin (EPO) drugs market is estimated to register a CAGR of X.X% in terms of value during forecast period 2018–2027. The report offers in-depth insights, revenue details, and other vital information regarding the global erythropoietin (EPO) drugs market, and the various trends, drivers, restraints, opportunities, and threats in the target market till 2027. The report offers insightful and detailed information regarding the various key players operating in the global erythropoietin (EPO) drugs market, their financials, supply chain trends, key developments, apart from future strategies, acquisitions & mergers, and market footprint. The global erythropoietin (EPO) drugs market report has been segmented on the basis of mechanism of action, target site, drug type, therapy, end-user and region.

Request Covid - 19 Impact

Erythropoietin is a hormone largely produce by the capillary network of renal cortex of the Kidney and also in minor quantity produce by liver and brain which stimulate the formation of red blood cells (RBCs). Erythropoietin (EPO), also known as hematopoietin or hemopoietin. Chemically, erythropoietin a protein with an attached sugar. It is glycoproteins that help to stimulate the growth of specific types of blood cells in the bone marrow. The kidney cells produce and release erythropoietin when the level of oxygen is very low in the blood. Erythropoietin drugs are used to treat anaemia caused due to chronic kidney diseases(CKD), cancer and human immunodeficiency virus (HIV). Normal levels of erythropoietin range from 4 up to 24 mU/ml (milliunits per millilitre).

Increasing prevalence of patients with chronic kidney dysfunction disease(CDK), cancer, acquired immune deficiency syndrome (AIDS) and bone marrow dysfunction are expected to drive the growth of erythropoietin drug market. Other factors include upsurge in drug patent expiration which in turn are shifting vendors to emphasize on using biosimilar medicines having same therapeutic effect with lower cost, growing geriatrics patient’s population, raising deficiency of iron, vitamin B12 and folic acid due to sedentary lifestyle and  increase in blood transfusion during surgeries and treatment (solid tumours, malignant lymphoma or multiple myeloma, cardiovascular status) are anticipated to drive the growth of EPO drug market worldwide.

Unaffordability of therapeutics medication process and longer duration of treatments are some of the factors that can inhibit the growth of the global EPO market to a certain extent.

Currently, EPO pills is in a nascent stage of development. Epogen or Procrit is most common medication used to aid patients with kidney disease who require dialysis to both treat and prevent anaemia. All the medicated drugs are injected intravenously (into a vein) or subcutaneously (under the skin) as a route of administration.

The global erythropoietin drug market report has been segmented on the basis of drug class, products, application and region. On the basis of region, the global erythropoietin (EPO) drugs market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Currently, the market in North America dominates the global erythropoietin drug market in terms of revenue owing to patent expiration of biologics, various players have entered the market in this region. The market in Asia Pacific is projected to have fastest growth with highest CAGR, owing to increasing incidence of chronic disease.

Market Segmentation:

Global erythropoietin (EPO) drugs market segmentation by drug class:

• Biologics
• Biosimilar

Global erythropoietin (EPO) drugs market segmentation by products:

• Epoetin-alfa
• Epoetin-beta
• Darbepoetin-alfa
• Others (pegylated erythropoietin, carbamylated erythropoietin)

Global erythropoietin (EPO) drugs market segmentation, by application:

• Cancer
• Hematology
• Renal Diseases
• Neurology

Global erythropoietin (EPO) drugs market segmentation by region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

• Johnson & Johnson LLC.
• Hospira Inc.
• Hoffmann-La Roche AG.
• Amgen Inc.
• Biocon Limited.
• Teva Pharmaceutical Industries Ltd.
• Ranbaxy Laboratories Ltd.
• Novartis International AG.
• Pfizer Inc.
• LG Life Sciences Limited.